Published • loading... • Updated
dorsaVi (ASX:DVL) Renews US Defense-Funded Study with Georgia Southern Targeting Soldier Injuries
Summary by Stocks Down Under
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
dorsaVi (ASX:DVL) Renews US Defense-Funded Study with Georgia Southern Targeting Soldier Injuries
A 12-month renewal that doubles as a field trial for the exoskeleton ambition. dorsaVi (ASX:DVL) has renewed its research agreement with Georgia Southern University for another 12 months, with the study funded by the US Department of Defense. The aim is to use dorsaVi’s wearable sensors to reduce stress fractures and lower limb injuries among military trainees in load-bearing field training. Stress fractures are one of the most expensive injurie…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
